Journal of Transplantation / 2017 / Article / Tab 3 / Clinical Study
The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial Table 3 Adverse events at year 3.
Everolimus ( ) CNI ( ) valueAny adverse event, (%) 28 (96.6) 16 (57.1) <0.001 Study drug discontinuation 10 (34.5) 0 <0.001 Infection 19 (65.5) 14 (50.0) 0.24 Infection with need for hospitalization 10 (34.5) 4 (14.3) 0.077 Neoplasm 2 (6.9) 3 (10.7) 0.67 Anemia 10 (34.5) 0 0.001 Leukopenia 6 (20.7) 1 (3.6) 0.10 Thrombocytopenia 1 (3.4) 0 1.0 Lower extremity edema 10 (34.5) 2 (7.1) 0.011 Skin rash 8 (27.6) 0 0.004 Oral aphtosis 5 (17.2) 0 0.052 Pulmonary toxicity 5 (17.2) 0 0.052 Diarrhea 7 (24.1) 2 (7.1) 0.14
CNI, calcineurin inhibitor.